Overview

Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.

Status:
Completed
Trial end date:
2020-06-19
Target enrollment:
Participant gender:
Summary
Compare safety and efficacy of BIBF 1120 versus sunitinib in patients with advanced RCC and to investigate the effects of BIBF 1120 on the heart rate (HR) corrected QT interval (QTcF).
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Nintedanib
Sunitinib